During treatment with anti-epidermal growth factor receptor antibody, skin disorders are considered major adverse drug reactions. Clinical features of skin disorders during panitumumab (Pmab) treatment for wild-type KRAS gene unresectable, advanced or recurrent colorectal cancer were analyzed as a post hoc analysis of a post-marketing surveillance study for Pmab. Information was collected during clinical courses for 10 months, or until discontinuation of Pmab for any reason. Among 3,085 patients, dermatitis acneiform occurred in 69.9% of the patients, paronychia in 24.2%, dry skin in 21.7%, and pruritus in 4.8%. Among the patients who experienced skin disorders, 6.9% of the patients withdrew from panitumumab therapy because of skin disorders. Topical corticosteroids, oral antibiotics, or emollients were usually administered for treatment of skin disorders. Approximately 80% of the patients with these adverse events recovered or were recovering. The incidence of dermatitis acneiform was significantly higher in males, patients who were <65 years who had heavier body weight, or who took a higher dose per 1 m
2 of body surface area.
View full abstract